Expression of CD164 on Malignant T cells in Sézary Syndrome

Publikation

Expression of CD164 on Malignant T cells in Sézary Syndrome

Wissenschaftlicher Artikel/Review - 01.05.2016

Guenova Emmanuella, Hoetzenecker Wolfram, French Lars E, Kazakov Dmitry V, Dummer Reinhard, Mitev Vanyo, Navarini Alexander A, Saulite Ieva, Mehra Tarun, Contassot Emmanuel, Chang Yun-Tsan, Desislava Ignatova, Cozzio Antonio

Zitation

Guenova E, Hoetzenecker W, French L, Kazakov D, Dummer R, Mitev V, Navarini A, Saulite I, Mehra T, Contassot E, Chang Y, Desislava I, Cozzio A. Expression of CD164 on Malignant T cells in Sézary Syndrome. Acta Derm Venereol 2016; 96:464-7.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Acta Derm Venereol 2016; 96

Veröffentlichungsdatum

01.05.2016

eISSN (Online)

1651-2057

Seiten

464-7

Kurzbeschreibung/Zielsetzung

Sézary syndrome is a primary cutaneous T-cell lymphoma characterized by pruritic erythroderma, peripheral lymphadenopathy and the presence of malignant T cells in the blood. Unequivocal detection of malignant cells in patients with Sézary syndrome is of important diagnostic, prognostic and therapeutic value. However, no single Sézary syndrome specific cell surface marker has been identified. In a cohort of patients with Sézary syndrome, CD164 expression on total CD4+ lymphocytes was significantly upregulated compared with healthy controls. CD164 expression was in most cases limited to CD4+CD26- malignant T lymphocytes, unequivocally identified using flow-cytometry by the expression of a specific Vβ clone for each patient. Increased expression of CD164 may be a promising diagnostic parameter and a potential target for a CD164-linked therapeutic approach in Sézary syndrome.